MedTrace Logo

Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma

NCT00026208 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2018-07-24

Study results available
· View outcomes & findings →

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with radiation therapy may kill more tumor cells.

PURPOSE: This phase 2 trial is studying how well giving combination chemotherapy together with low-dose radiation therapy works in treating patients with stage I or stage IIA Hodgkin's lymphoma.

Conditions

  • Lymphoma, Hodgkin Disease
  • Lymphoma
  • Hodgkin Disease
  • Lymphoma: Hodgkin

Interventions

DRUG

Vincristine

1.4 mg/m² intravenously (IV) on week 2, 4, 6, 8

DRUG

Cyclophosphamide

650 mg/m², on week 1 and 5

DRUG

Doxorubicin

25 mg/m², on week 1, 3, 5, 7

DRUG

Prednisone

40 mg/m², oral, every other day. Taper-reduction 10 mg/m² every other day during last 2 weeks of chemotherapy

DRUG

Bleomycin

5 u/m² intravenously (IV) on week 2, 4, 6, 8

DRUG

Etoposide

60 mg/m² x 2 intravenously (IV) on week 3, 7 (d 15, 16, 43, 44)

RADIATION

Low-dose radiotherapy (RT)

20 Grey (Gy) modified involved field radiotherapy administered as consolidative irradiation will beginning between 2 and 12 weeks after the completion of Stanford V-C chemotherapy regimen.

Sponsors & Collaborators

Principal Investigators

  • Ranjana H Advani, MD · Stanford University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-06-30
Primary Completion
2013-04-26
Completion
2017-02-13
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00026208 on ClinicalTrials.gov